The current status, challenges, and future developments of new tuberculosis vaccines

被引：77

作者：

Gong, Wenping ^{[1
]}

Liang, Yan ^{[1
]}

Wu, Xueqiong ^{[1
]}

机构：

[1] Inst TB Res, Beijing Key Lab New Tech TB Diag & Treatment, Army TB Prevent & Control Key Laboratory, 309th Hosp Chinese PLA,17 Heishanhu Rd, Beijing 100091, Peoples R China

来源：

HUMAN VACCINES & IMMUNOTHERAPEUTICS | 2018年 / 14卷 / 07期

关键词：

BCG; Clinical trials; Immunology; Mycobacterium tuberculosis; Tuberculosis; Vaccines; BACILLUS-CALMETTE-GUERIN; BCG COEXPRESSING AG85B; MYCOBACTERIUM-INDICUS-PRANII; MEDIATED IMMUNE-RESPONSE; ENHANCED CELLULAR IMMUNE; CHIMERIC DNA VACCINE; PROTECTIVE EFFICACY; FUSION PROTEIN; SUBUNIT VACCINE; TB VACCINE;

D O I：

10.1080/21645515.2018.1458806

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

Mycobacterium tuberculosis complex causes tuberculosis (TB), one of the top 10 causes of death worldwide. TB results in more fatalities than multi-drug resistant (MDR) HIV strain related coinfection. Vaccines play a key role in the prevention and control of infectious diseases. Unfortunately, the only licensed preventive vaccine against TB, bacilli Calmette-Guerin (BCG), is ineffective for prevention of pulmonary TB in adults. Therefore, it is very important to develop novel vaccines for TB prevention and control. This literature review provides an overview of the innate and adaptive immune response during M. tuberculosis infection, and presents current developments and challenges to novel TB vaccines. A comprehensive understanding of vaccines in preclinical and clinical studies provides extensive insight for the development of safer and more efficient vaccines, and may inspire new ideas for TB prevention and treatment.

引用

页码：1697 / 1716

页数：20

共 50 条

[1] New Vaccine Against Tuberculosis:Current Developments and Future Challenges
Jun Liu (Department of Molecular Genetics
[J]. Science Foundation in China, 2009, 17 (02) : 50 - 56
[2] Tuberculosis: Current status and recent developments in diagnostics, drugs and vaccines
Duncan, K
[J]. EXPERT OPINION ON THERAPEUTIC PATENTS, 1996, 6 (02) : 175 - 185
[3] Vaccines against gonorrhea: Current status and future challenges
Jerse, Ann E.
Bash, Margaret C.
Russell, Michael W.
[J]. VACCINE, 2014, 32 (14) : 1579 - 1587
[4] ANTI-HIV VACCINES - CURRENT STATUS AND FUTURE-DEVELOPMENTS
NORLEY, SG
VOGEL, T
KURTH, R
[J]. DRUGS, 1993, 46 (06) : 947 - 960
[5] Current Developments and Challenges of mRNA Vaccines
Chen, Jinjin
Chen, Jianzhu
Xu, Qiaobing
[J]. ANNUAL REVIEW OF BIOMEDICAL ENGINEERING, 2022, 24 : 85 - 109
[6] Vaccines in support of globalisation: the current status of coronavirus and future implementation challenges
Pavlakis, G.
[J]. EUROPEAN JOURNAL OF PUBLIC HEALTH, 2020, 30
[7] Special Lecture: Rotavirus and Rotavirus Vaccines: Current status and future challenges
Glass, Roger
[J]. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2017, 74 : 43 - 43
[8] Zika virus vaccines: immune response, current status, and future challenges
Richner, Justin M.
Diamond, Michael S.
[J]. CURRENT OPINION IN IMMUNOLOGY, 2018, 53 : 130 - 136
[9] Current challenges and future developments
Suzuki, Daijiro
[J]. ZKG INTERNATIONAL, 2021, 74 (05): : 16 - 17
[10] Coupled data assimilation at ECMWF: current status, challenges and future developments
de Rosnay, Patricia
Browne, Philip
de Boisseson, Eric
Fairbairn, David
Hirahara, Yoichi
Ochi, Kenta
Schepers, Dinand
Weston, Peter
Zuo, Hao
Alonso-Balmaseda, Magdalena
Balsamo, Gianpaolo
Bonavita, Massimo
Borman, Niels
Brown, Andy
Chrust, Marcin
Dahoui, Mohamed
Chiara, Giovanna
English, Stephen
Geer, Alan
Healy, Sean
Hersbach, Hans
Laloyaux, Patrick
Magnusson, Linus
Massart, Sebastien
McNally, Anthony
Pappenberger, Florian
Rabier, Florence
[J]. QUARTERLY JOURNAL OF THE ROYAL METEOROLOGICAL SOCIETY, 2022, 148 (747) : 2672 - 2702

← 1 2 3 4 5 →